HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early withdrawal of cyclosporine A improves 1-year kidney graft structure and function in sirolimus-treated patients.

AbstractBACKGROUND:
Chronic allograft nephropathy (CAN) represents the most common cause of late graft loss. Nephrotoxicity from chronic use of calcineurin inhibitors (CNI) has the potential to contribute to CAN. The present investigation aimed to evaluate the impact of early CNI withdrawal on kidney graft function and structure at 1 year in sirolimus (SRL)-treated patients.
METHODS:
Forty consecutive kidney transplant recipients were initially treated with corticosteroids, cyclosporine A (CsA), and SRL (2 mg/day). After 3 months, patients were randomly assigned to either continue the same treatment (group I) or to withdraw CsA and continue SRL (group II). All patients underwent kidney graft biopsy immediately after graft reperfusion (0-hr biopsy) and 12 months after engraftment.
RESULTS:
Baseline graft biopsy showed a higher degree of renal damage in group II patients (total score, 4+/-1.6 vs. 2+/-0.9; P<0.05). Twelve months after engraftment, CAN was diagnosed in 55% of all patients, of whom 64% were in group I and 36% in group II. CAN lesions were scored as moderate to severe in 90% of group I patients but only 32% of group II patients (P<0.05). A vascular score greater than or equal to 2 occurred in 90% of group I patients and in 38% of group II patients (P<0.05). At 1 year, group I patients showed a significantly worse kidney graft function (serum creatinine, 2.0+/-0.3 vs. 1.3+/-0.3 mg/dL; creatinine clearance, 54+/-14 vs. 66+/-17 mL/min; both P<0.002).
CONCLUSIONS:
These results suggest that early withdrawal of CsA is a safe option, which allows a significant reduction of chronic histologic damage, particularly vascular injury, of cadaveric kidney allografts.
AuthorsGiovanni Stallone, Salvatore Di Paolo, Antonio Schena, Barbara Infante, Giuseppe Grandaliano, Michele Battaglia, Loreto Gesualdo, Francesco Paolo Schena
JournalTransplantation (Transplantation) Vol. 75 Issue 7 Pg. 998-1003 (Apr 15 2003) ISSN: 0041-1337 [Print] United States
PMID12698087 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Chemical References
  • Immunosuppressive Agents
  • Cyclosporine
  • Sirolimus
Topics
  • Adult
  • Aged
  • Chronic Disease
  • Cyclosporine (administration & dosage)
  • Drug Administration Schedule
  • Female
  • Humans
  • Immunosuppressive Agents (administration & dosage, therapeutic use)
  • Kidney (pathology, physiopathology)
  • Kidney Diseases (etiology, pathology, physiopathology)
  • Kidney Transplantation (adverse effects)
  • Male
  • Middle Aged
  • Sirolimus (therapeutic use)
  • Transplantation, Homologous
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: